Clinical Trial Update: Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating tuvusertib in combination with niraparib or lartesertib in participants with epithelial ovarian cancer; the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Ovarian Cancer

Drugs mentioned

• Lartesertib (lartesertib)
• Niraparib (Niraparib)
• Tuvusertib (tuvusertib)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Ovarian Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING